CryoLife remains bullish over FDA warning
This article was originally published in Clinica
US tissue implants company CryoLife, which last month was issued with a warning letter following an FDA inspection in March and April, maintains that the whole affair, while unwanted, will be able to yield some positives. Vice-president of corporate communications Roy Vogeltanz told Clinica that the public's understanding of the FDA system will have improved in the wake of the inspections (see No Clinica 1013, p 15).
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.